Core Points - The company and its board members guarantee the authenticity, accuracy, and completeness of the quarterly report, assuming legal responsibility for any misrepresentation or omissions [2][3][5] - The quarterly financial report has not been audited [8] Financial Data - The company does not require retrospective adjustments or restatements of previous accounting data [3] - There are no non-recurring profit and loss items applicable for the current reporting period [3] - The company has not defined any non-recurring profit and loss items as recurring [3] Shareholder Information - The company has not reported any changes in the top ten shareholders or any significant shareholders participating in securities lending [5] - The company received an administrative penalty notice from the China Securities Regulatory Commission, but it assesses that this will not significantly impact its operations [5] Financial Statements - The company has provided consolidated balance sheets and profit statements for the reporting period, with no net profit reported from mergers under common control [6][7]

Financial Performance - The company's operating revenue for Q3 2025 reached ¥94,498,587.86, representing a year-on-year increase of 19.01%[5] - Net profit attributable to shareholders for Q3 2025 was ¥1,711,738.22, a significant increase of 161.26% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥1,353,870.99, up 144.51% year-on-year[5] - Basic earnings per share for Q3 2025 were ¥0.0034, reflecting a 161.32% increase from the previous year[5] - The total profit for Q3 2025 was ¥25,741,005.94, marking a 435.45% increase year-on-year, primarily due to increased operating income[9] - Net profit for the period was ¥21,794,297.70, significantly higher than ¥2,873,345.95 in the previous period, marking an increase of 658.73%[20] - The total comprehensive income for the period reached ¥20,783,297.70, a significant increase from ¥2,873,345.95 in the previous period[21] - Basic and diluted earnings per share both improved to ¥0.0429, compared to ¥0.0057 in the prior period[21] Assets and Liabilities - Total assets at the end of Q3 2025 amounted to ¥774,726,400.45, a decrease of 7.64% from the end of the previous year[5] - The company's total assets decreased to ¥774,726,400.45 from ¥838,820,451.71, a decline of 7.66%[18] - Current assets totaled ¥466,108,240.34, down 15.77% from ¥553,758,364.26 at the beginning of the period[17] - Non-current assets increased to ¥308,618,160.11, up from ¥285,062,087.45, representing an increase of 8.25%[17] - The company's total liabilities decreased to ¥65,718,005.22 from ¥80,599,696.61, a reduction of 18.43%[18] - The equity attributable to shareholders decreased to ¥709,008,395.23 from ¥758,220,755.10, a decline of 6.48%[18] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥71,227,192.33, a decline of 489.39% compared to the previous year[5] - The net cash flow from operating activities for the first nine months of 2025 was -71,227,192.33 RMB, a decrease of 489.39% compared to 18,291,801.37 RMB in the same period of 2024[10] - Cash received from other operating activities increased by 1235.39% to 52,537,639.24 RMB, primarily due to the recovery of inter-company loans from a related party[10] - The cash outflow for investing activities was -64,578,523.83 RMB, representing a 41.32% increase from -45,695,886.29 RMB in the previous year, mainly due to increased long-term asset investments[10] - The cash and cash equivalents at the end of the period decreased by 36.45% to 127,892,923.27 RMB, attributed to stock repurchases and investment expenditures[10] - Cash inflow from operating activities totaled ¥332,072,556.68, slightly up from ¥322,546,142.28 year-over-year[22] - The net cash flow from investing activities was -¥64,578,523.83, compared to a positive ¥90,493,577.13 last year[22] - The net cash flow from financing activities was -¥69,995,657.57, worsening from -¥25,401,080.43 in the previous period[22] - The ending cash and cash equivalents balance decreased to ¥127,892,923.27 from ¥216,891,217.73 year-over-year[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,483, with no preferred shareholders[11] - The largest shareholder, Dongfang Securities Co., Ltd., holds 10.28% of the shares, amounting to 52,148,000 shares[12] - The second-largest shareholder, Yangtianhe Pharmacy Co., Ltd., owns 7.00% of the shares, totaling 35,525,690 shares[12] Administrative and Regulatory Matters - The company received an administrative penalty notice from the China Securities Regulatory Commission, but it does not expect significant impacts on its operations[14] - The company did not undergo an audit for the third quarter financial report[23] - The financial report for the third quarter was released on October 29, 2025[24] Research and Development - Research and development expenses for the period were ¥7,167,677.83, compared to ¥5,583,739.76 in the previous period, indicating an increase of 28.48%[19] Other Financial Metrics - Accounts receivable increased by 76.25% to ¥135,696,791.67, attributed to relaxed credit policies and extended payment cycles for some customers[8] - Prepayments surged by 4723.06% to ¥78,816,564.06, mainly due to investments in drug approvals and R&D[8] - The company reported a 443.95% increase in operating profit, reaching ¥25,640,486.44, driven by higher revenue and reduced expenses[9] - Total operating revenue for the period reached ¥293,436,251.95, an increase of 13.03% compared to ¥259,604,624.04 in the previous period[19] - Total operating costs amounted to ¥266,450,162.51, up from ¥256,532,928.46, reflecting a growth of 3.56%[19] - The company reported a financial asset impairment loss of ¥1,296,086.72, compared to a loss of ¥353,872.07 in the previous period[20]

Group 1 - The company has completed the establishment of a securities account for its 2024 employee stock ownership plan, with the account opened on October 23, 2025 [1][2] - The company currently does not hold any stocks under the 2024 employee stock ownership plan and will continue to monitor its implementation progress [2] - The company has disclosed the relevant documents regarding the securities account opening [3] Group 2 - The company's wholly-owned subsidiary, Jiying Pharmaceutical (Hunan) Co., Ltd., has changed its business scope and completed the industrial and commercial registration [4][5] - The new business scope includes drug production, drug wholesale and retail, food production and sales, and other related activities [5] - The subsidiary has obtained a new business license reflecting these changes [6]

2025 年第二次临时股东大会会议资料 广东嘉应制药股份有限公司 GUANGDONG JIAYING PHARMACEUTICAL CO.,LTD 2025年第二次临时股东大会 会议资料 - 1 - 股票简称：嘉应制药 股票代码：002198 会议日期：二〇二五年十月三十一日 2025 年第二次临时股东大会会议资料 2025 年第二次临时股东大会须知 根据《上市公司股东大会规则》、《股东大会议事规则》等相关规定，为维护投资者 的合法权益，确保广东嘉应制药股份有限公司（以下简称"公司"）2025 年第二次临时股 东大会的顺利召开，特制定会议须知如下，望出席股东大会全体人员遵守: 1、各股东请按照本次股东大会会议通知（2025 年 10 月 16 日刊登在《证券时报》、 《证券日报》、《中国证券报》及巨潮资讯网 http://www.cninfo.com.cn 的《关于召开 2025 年第二次临时股东大会的通知》）中规定的时间和登记方法办理参加会议手续，证明文件 不齐或手续不全的，谢绝参会。 2、参与融资融券业务持有公司股份的股东，如选择网络投票可将投票意向告知受托证 券公司再由证券公司为投资者进行投票或股东直接 ...

Core Points - The company announced a change in the business scope of its wholly-owned subsidiary, Jiying Pharmaceutical (Hunan) Co., Ltd. [2] - The business scope change was completed due to the company's development needs, and the subsidiary has obtained a new business license following the registration process [2]

Core Viewpoint - The company has approved a revised employee stock ownership plan for 2024, indicating a commitment to employee engagement and potential future growth [2] Group 1: Employee Stock Ownership Plan - The company announced the approval of the revised 2024 employee stock ownership plan during the board meeting held on October 15, 2025 [2] - The securities accounts for the 2024 employee stock ownership plan have been successfully opened as of the announcement date [2] - Currently, the 2024 employee stock ownership plan does not hold any company stock, and the company will monitor its implementation and fulfill disclosure obligations as required [2]

证券代码：002198 证券简称：嘉应制药 公告编号：2025-058 广东嘉应制药股份有限公司（以下简称"公司"）全资子公司嘉应制药（湖 南）有限公司（以下简称"嘉应湖南"）因业务发展需要，对其经营范围进行了变 更。近日，嘉应湖南已完成工商变更登记手续并取得了《营业执照》，具体变更 情况如下： 变更事项 变更前 变更后 经营范围 生产、销售片剂、颗粒剂、硬胶囊剂； 研究、开发药品、食品；销售五金、 交电、建筑材料、摩托车及汽车配件、 针纺织品、金属材料、化工原料（不 含危险和监控化学品）；经营商品和 技术的进出口业务。 许可项目：药品生产；药品委托生产；药品进出 口；药品批发；药品零售；食品生产；食品销售； 保健食品生产；医用口罩生产；化妆品生产。(依 法须经批准的项目，经相关部门批准后方可开展 经营活动，具体经营项目以相关部门批准文件或 许可证件为准)一般项目：医学研究和试验发展； 医学研究和试验发展(除人体干细胞、基因诊断与 治疗技术开发和应用)；金属材料销售；化工产品 销售(不含许可类化工产品)；货物进出口；技术服 务、技术开发、技术咨询、技术交流、技术转让、 技术推广；技术进出口；初级农产品收购；农 ...

证券代码：002198 证券简称：嘉应制药 公告编号：2025-057 广东嘉应制药股份有限公司 一、本次员工持股计划证券账户开户情况 截至本公告日，公司2024年员工持股计划的证券账户已经开立完成，具体情 况如下： 1、账户名称：广东嘉应制药股份有限公司—2024 年员工持股计划； 2、账户号码：0899504184； 关于公司 2024 年员工持股计划完成开户的公告 本公司及全体董事会成员保证本公告内容的真实、准确和完整，不存在虚 假记载、误导性陈述或者重大遗漏。 广东嘉应制药股份有限公司（以下简称"公司"）于 2025 年 10 月 15 日召 开的第七届董事会第九次临时会议，审议通过了《广东嘉应制药股份有限公司 2024 年员工持股计划（修订稿）》《广东嘉应制药股份有限公司 2024 年员工持 股计划管理办法（修订稿）》。详见公司于 2025 年 10 月 16 日在《证券时报》 《中国证券报》《证券日报》及巨潮资讯网（www.cninfo.com.cn）上披露的相关 公告。 根据中国证监会《关于上市公司实施员工持股计划试点的指导意见》及深圳 证券交易所《上市公司信息披露指引第1号——主板上市公司规范 ...

证券代码：002198 证券简称：嘉应制药 公告编号：2025-052 一、修订《公司章程》的情况 根据《中华人民共和国公司法》（以下简称"《公司法》"）以及《上市公 司章程指引》等相关法律法规的规定，并结合公司自身实际情况，公司拟对《广 东嘉应制药股份有限公司章程》进行修订。 上述事项尚需提交公司股东大会审议，同时，公司董事会提请股东大会授权 相关人员办理工商变更登记、章程备案等相关事项，具体变更内容以市场监督管 理部门核准、登记的情况为准。 《公司章程》修订对照表及修订后的《公司章程》全文详见同日披露于巨潮 资讯网(www.cninfo.com.cn)。 特此公告。 广东嘉应制药股份有限公司董事会 广东嘉应制药股份有限公司 关于修订<公司章程>并办理工商变更登记的的公告 本公司及董事会保证本公告内容的真实、准确和完整，不存在虚假记载、误导 性陈述或者重大遗漏。 广东嘉应制药股份有限公司（以下简称"公司"）于2025年10月15日召开第 七届董事会第九次临时会议，审议通过了《关于修订<公司章程>并办理工商变 更登记的议案》。现将有关情况公告如下： 2025 年 10 月 16 日 ...

证券简称：嘉应制药 证券代码：002198 广东嘉应制药股份有限公司 2024 年员工持股计划 （修订稿） 二〇二五年十月 1 声明 本公司及全体董事、监事保证本员工持股计划不存在虚假记载、误导性陈述 或重大遗漏，并对其真实性、准确性、完整性承担个别和连带的法律责任。 2 特别提示 本部分内容中的词语简称与"释义"部分保持一致。 风险提示 本部分内容中的词语简称与"释义"部分保持一致。 1、本员工持股计划遵循依法合规、自愿参与、风险自担原则，若员工认购 金额较低时，本员工持股计划存在无法成立的风险；若员工认购资金不足，本员 工持股计划存在低于预计规模的风险。 2、有关本员工持股计划的具体的资金来源、出资金额、参与对象等均属初 步方案，能否完成实施，存在不确定性。 3、本员工持股计划中有关公司业绩考核指标的描述不代表公司的业绩预测， 亦不构成业绩承诺。 4、公司后续将根据规定披露相关进展情况，敬请广大投资者谨慎决策，注 意投资风险。 3 1、《广东嘉应制药股份有限公司 2024 年员工持股计划》（以下简称"员工 持股计划"或"本员工持股计划"）系广东嘉应制药股份有限公司（以下简称"嘉 应制药"或"公司"）依据《 ...